tiprankstipranks
Trending News
More News >

Mirati Therapeutics downgraded to Market Perform from Outperform at Leerink

Leerink analyst Andrew Berens downgraded Mirati Therapeutics to Market Perform from Outperform with a price target of $58, down from $78.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on MRTX:

Disclaimer & DisclosureReport an Issue

1